Short-term use of glucocorticoids and risk of peptic ulcer bleeding: A nationwide population-based case-crossover study

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 5, 2015, Pages 599-606

  Tseng, C L ^a,b   Chen, Y T ^a,c   Huang, C J ^a,b   Luo, J C ^a,b   Peng, Y L ^a,b   Huang, D F ^a,b   Hou, M C ^a,b   Lin, H C ^a,b   Lee, F Y ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; DRUG COMBINATION; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MIDDLE AGED; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT COURSE THERAPY; CASE CONTROL STUDY; CHEMICALLY INDUCED; CROSSOVER PROCEDURE; DRUG ADMINISTRATION; DRUG COMBINATION; FACTUAL DATABASE; HOSPITALIZATION; LONGITUDINAL STUDY; METHODOLOGY; PEPTIC ULCER HEMORRHAGE; STATISTICAL MODEL; TAIWAN; TIME FACTOR;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; CROSS-OVER STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEPTIC ULCER HEMORRHAGE; RESEARCH DESIGN; TAIWAN; TIME FACTORS;

EID: 84938556185     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13298     Document Type: Article

References (36)

1. Rahme E, Barkun AN, Adam V, Bardou M,. Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs. Drug Saf 2004; 27: 1019-42.
2. Ko JK, Cho CH,. Alcohol drinking and cigarette smoking: a "partner" for gastric ulceration. J Chin Med Assoc 2000; 63: 845-54.
3. Bombardier C, Laine L, Reicin A, et al,. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
4. Marshall BJ, Goodwin CS, Warren JR, et al,. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2: 1437-42.
5. Chiorean MV, Locke GR 3rd, Zinsmeister AR, et al,. Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease. Am J Gastroenterol 2002; 97: 3015-22.
6. Leontiadis GI, Sharma VK, Howden CW,. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005; 330: 568.
7. Coelho MM, Luheshi G, Hopkins SJ, et al,. Multiple mechanisms mediate antipyretic action of glucocorticoids. Am J Physiol 1995; 269: R527-35.
8. Almawi WY, Melemedjian OK, Rieder MJ,. An alternate mechanism of glucocorticoid anti-proliferative effect: promotion of a Th2 cytokine-secreting profile. Clin Transplant 1999; 13: 365-74.
9. De Bosscher K, Vanden Berghe W, Haegeman G,. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000; 109: 16-22.
10. Conn HO, Blitzer BL,. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976; 294: 473-9.
11. Luo JC, Chang FY, Chen TS, et al,. Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy. Br J Clin Pharmacol 2009; 68: 252-9.
12. Messer J, Reitman D, Sacks HS, et al,. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983; 309: 21-4.
13. Hernandez-Diaz S, Rodriguez LA,. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001; 153: 1089-93.
14. Narum S, Westergren T, Klemp M,. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open 2014; 4: e004587.
15. Yokota A, Taniguchi M, Takahira Y, Tanaka A, Takeuchi K,. Dexamethasone damages the rat stomach but not small intestine during inhibition of COX-1. Dig Dis Sci 2007; 52: 1452-61.
16. Luo JC, Shin VY, Liu ES, et al,. Non-ulcerogenic dose of dexamethasone delays gastric ulcer healing in rats. J Pharmacol Exp Ther 2003; 307: 692-8.
17. Hsiang KW, Ng YY, Lu CL, et al,. Corticosteroids therapy and peptic ulcer disease in nephrotic syndrome patients. Br J Clin Pharmacol 2010; 70: 756-61.
18. Luo JC, Leu HB, Hou MC, et al,. Nonpeptic ulcer, nonvariceal gastrointestinal bleeding in hemodialysis patients. Am J Med 2013; 126: 264. e25-32
19. Cheng CL, Kao YH, Lin SJ, et al,. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011; 20: 236-42.
20. Lin CC, Lai MS, Syu CY, et al,. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 2005; 104: 157-63.
21. Luo JC, Leu HB, Hou MC, et al,. Cirrhotic patients at increased risk of peptic ulcer bleeding: a nationwide population-based cohort study. Aliment Pharmacol Ther 2012; 36: 542-50.
22. Maclure M,. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-53.
23. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S,. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006; 17: 268-75.
24. Delaney JA, Suissa S,. The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res 2009; 18: 53-65.
25. Wang YP, Chen YT, Tsai CF, et al,. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry 2014; 171: 54-61.
26. Luo JC, Leu HB, Huang KW, et al,. Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. CMAJ 2011; 183: E1345-51.
27. Maclure M, Mittleman MA,. Should we use a case-crossover design? Annu Rev Public Health 2000; 21: 193-221.
28. StataCorp. Stata 11 Base Reference Manual. College Station, TX: Stata Press, 2009.
29. Mager DE, Lin SX, Blum RA, et al,. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol 2003; 43: 1216-27.
30. Hoes JN, Jacobs JW, Boers M, et al,. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66: 1560-7.
31. Saag KG, Koehnke R, Caldwell JR, et al,. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115-23.
32. Okazaki K, Chiba T, Hajiro K,. Downregulation of gastric mucin gene expression and its biosynthesis by dexamethasone in the human. J Clin Gastroenterol 1998; 27 (Suppl. 1): S91-6.
33. Bandyopadhyay U, Biswas K, Bandyopadhyay D, et al,. Dexamethasone makes the gastric mucosa susceptible to ulceration by inhibiting prostaglandin synthetase and peroxidase-two important gastroprotective enzymes. Mol Cell Biochem 1999; 202: 31-6.
34. Luo JC, Shin VY, Liu ESL, et al,. Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. Eur J Pharmacol 2004; 485: 275-81.
35. Piper JM, Ray WA, Daugherty JR, Griffin MR,. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735-40.
36. Haukka J, Suvisaari J, Tuulio-Henriksson A, Lonnqvist J,. High concordance between self-reported medication and official prescription database information. Eur J Clin Pharmacol 2007; 63: 1069-74.